Pulse Medical

Guangdong Pulse Medical Technology Co., Ltd. is a high-tech enterprise focused on the development, manufacturing, and sales of cardiovascular medical devices. Founded in December 2014 by Ruan Chengmin, the company is headquartered in the Zhuhai National High-Tech Industrial Development Zone. Mr. Ruan has over two decades of experience in the research, development, and sales of cardiovascular medical devices and holds a medical background. Pulse Medical operates with a strategic focus on original research and development for high-end cardiovascular implantable and interventional medical devices, aiming to provide alternatives to imported products.

The company's business model is centered on a deep integration of medicine and engineering, referred to as the "medical-industrial integration" model. This approach involves close collaboration between clinical medical experts, who provide insights into the shortcomings of existing devices and patient needs, and the company's engineering and technical personnel to drive product optimization and innovation. Pulse Medical generates revenue through the sale of its developed medical devices to healthcare facilities. The company has successfully raised capital through multiple funding rounds, including a Series A in May 2019, a nearly CNY 100 million Series B in December 2020, and a Series C round in August 2022.

Pulse Medical's product pipeline is segmented into four main categories: cardiovascular implantable products, cardiovascular interventional products, sheath products, and intelligent monitoring and rehabilitation products. A key product is the Leftear® Left Atrial Appendage (LAA) Occluder System, which is designed for patients with atrial fibrillation to prevent strokes. This device is noted as the world's first "double-disk inner plug" LAA occluder, combining the advantages of both inner plug and outer cover occluders while considering the anatomical features of Chinese patients and the operating habits of Chinese surgeons. In April 2024, Pulse Medical entered a strategic cooperation agreement with Johnson & Johnson Medical Technology to jointly promote the Leftear® system, aiming to expand market reach and enhance treatment solutions for atrial fibrillation in China. Other products in development include a biodegradable patent foramen ovale (PFO) occluder and a transcatheter biological mitral and tricuspid valve.

Keywords: cardiovascular medical devices, structural heart disease, medical-industrial integration, left atrial appendage occluder, LAA occluder, Leftear, atrial fibrillation treatment, stroke prevention, interventional cardiology, medical device manufacturing, PFO occluder, Ruan Chengmin, Zhuhai, China medtech, cardiovascular implants, minimally invasive therapy, Johnson & Johnson partnership, import substitution, clinical collaboration, heart valve repair